1. Home
  2. For Industry
  3. Medical Products for Rare Diseases and Conditions
  4. FDA Rare Disease Innovation Hub
  5. Rare Disease Innovation, Science, and Exploration (RISE) Workshop Series
  6. RISE Workshop 4 - RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations
  1. Rare Disease Innovation, Science, and Exploration (RISE) Workshop Series

RISE Workshop 4 - RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations

The Rare Disease Innovation Hub's fourth RISE Workshop, entitled RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations, took place on September 29, 2026. This workshop explored statistical considerations in the design, conduct, and analysis of clinical investigations for rare disease medical products. The small patient populations inherent to rare disease present unique challenges that increase the risk of obtaining inconclusive trial results. Addressing these challenges requires careful attention to statistical rigor while utilizing tailored approaches that are necessary to make medical product development feasible in this space. Reliable and timely evidence that relies on data from all available information is critically important to patients and families affected by rare diseases, making the optimization of clinical investigation design, conduct, and analysis a matter of both scientific and ethical urgency.

The workshop focused on key statistical considerations for tailored approaches employed across the full arc of rare disease development programs. Topics included the role of randomization and blinding, strategies for enhancing efficiency, and factors specific to medical devices. Discussions explored these statistical considerations with the goal of identifying efficient approaches that maintain scientific rigor and produce meaningful results for rare disease product development.

Statistical considerations affect every aspect of drug development, testing, and review, including clinical trial design and measuring product effectiveness; understanding the role of statistical review is important for sponsors, patients, and disease advocates alike.

Meeting materials and a full recording are available at RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations.

Back to Top